Study Evaluating Venlafaxine ER in Recurrent Depression

Wyeth is now a wholly owned subsidiary of Pfizer1,096 enrolled

Overview

The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

1,096

Conditions

Depressive Disorder, Major Recurrence

Interventions

Venlafaxine ERDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Clinical diagnosis for recurrent major depression Exclusion Criteria * The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant * Known hypersensitivity to venlafaxine or fluoxetine * History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.